Provided by Tiger Fintech (Singapore) Pte. Ltd.

AlloVir, Inc.

9.81
0.0000
Volume:- -
Turnover:94.38K
Market Cap:49.21M
PE:-0.84
High:9.81
Open:9.81
Low:9.81
Close:9.81
52wk High:24.15
52wk Low:7.96
Shares:5.02M
Float Shares:1.73M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-11.7340
EPS(LYR):-11.7340
ROE:-45.37%
ROA:-22.33%
PB:0.43
PE(LYR):-0.84

Loading ...

Company Profile

Company Name:
AlloVir, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.